The DOI matches its Crossref record; 445 of the 458 references it cites were found in a registry or an index, and 13 are not checked yet.
Harnessing Dietary Tryptophan: Bridging the Gap Between Neurobiology and Psychiatry in Depression Management
Open accessAbstract
Major depressive disorder remains a leading cause of disability worldwide, with conventional antidepressants offering incomplete and often transient relief. Mounting evidence highlights disturbances in tryptophan (Trp) metabolism as a key biological axis linking inflammation, neuroplasticity, and mood regulation. Plant-derived compounds that modulate this pathway, including 5-hydroxytryptophan, isoflavones, berberine, and polyphenols, have emerged as promising candidates for integrative treatment strategies. Yet, despite encouraging preclinical and clinical findings, knowledge gaps persist regarding long-term efficacy, mechanistic specificity, and standardized therapeutic protocols. This narrative review explores how Trp modulators influence central and peripheral mechanisms relevant to depression, from serotonergic synthesis and kynurenine shunting to gut–brain–immune interactions. Evidence from animal models and randomized clinical trials is critically synthesized, with particular attention to outcomes on mood stabilization, anxiety reduction, cognitive function, and sleep regulation. Special emphasis is placed on translational potential, methodological limitations, and the need for harmonized research frameworks. Here we highlight that phytochemical interventions represent a mechanistically informed and biocompatible strategy for advancing depression management. By bridging neurobiology and clinical psychiatry, these insights may pave the way for next-generation therapeutics that integrate dietary, microbiota-targeted, and anti-inflammatory approaches. Broader application of this research could ultimately refine personalized psychiatry, expand therapeutic horizons, and contribute to global mental health resilience.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Tryptophan (Trp) metabolism through the kynurenine (KYN) pathway: balancing neuroprotection and neurotoxicity in depression. This figure illustrates how immune-mediated activation of the KYN pathway disrupts Trp metabolism, linking inflammation with depression-related neuropathology. The stress hormone cortisol stimulates tryptophan 2,3-dioxygenase (TDO). Pro-inflammatory cytokines [interferon (IFN)-alpha (α), IFN-beta (β), IFN-gamma (γ), tumor necrosis factor alpha (TNF-α)] and lipopolysaccharide (LPS) induce indoleamine 2,3-dioxygenases (IDOs), diverting Trp away from serotonin (5-HT) synthesis toward KYN production. In contrast, anti-inflammatory cytokines [interleukin (IL)-4, IL-10] and superoxide dismutase (SOD) counteract this process. Oxygen molecule (O2), IFN-β, IFN-γ, and TNF-α stimulate and IL-4, IL-10, and SOD suppress kynurenine 3-monooxygenase (KMO). Furthermore, IDOs, TDO, and KMO activities are influenced by positive and negative feedback loops. Peripheral KYN crosses the blood–brain barrier, where it undergoes two competing fates: (i) conversion into kynurenic acid (KYNA), a putative neuroprotective N-Methyl-D-Aspartate (NMDA) receptor antagonist with putative antioxidant properties, or (ii) metabolism into 3-hydroxykynurenine (3-HK) and quinolinic acid (QA), which promotes reactive oxygen species (ROS), NMDA receptor overstimulation, mitochondrial dysfunction, and neuronal apoptosis, ultimately leading to neurodegeneration. The dashed inhibitory arrow indicates that enhanced KYN metabolism reduces 5-HT and melatonin synthesis, impairing neurotransmission and neuroprotection. The balance between KYNA and QA determines whether the KYN pathway promotes resilience or vulnerability to depression. Abbreviations: ↑, Increase.](https://figures.cochat.ai/paper-figures/cc16b0b7ddf143b5864943d377b69c49/harnessing-dietary-tryptophan-bridging-the-gap-between-neurobiology-and-figure-2.jpg)




![Figure 7 Mechanistic actions of phytochemicals in depression. Phytochemicals, including 5-hydroxytryptophan (5-HTP), isoflavones, berberine, and polyphenols, exert central effects through modulation of the gut microbiome (via tryptophan [Trp] metabolism), regulation of immune signaling (attenuation of inflammation), and stimulation of neurogenesis (enhancement of plasticity and mood stabilization), collectively contributing to antidepressant outcomes.](https://figures.cochat.ai/paper-figures/ed95233c9b524d19b071d6bd870bc145/harnessing-dietary-tryptophan-bridging-the-gap-between-neurobiology-and-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At the systems scale, deficits in hippocampal and prefrontal plasticity seen in susceptible strains are reversible when interventions reset both synaptic strength and excitability, whether via pharmacology, experience-dependent enrichment, electroconvulsive therapy, or molecular levers such as SIRT1 that couple intrinsic firing properties to synaptic throughput [12,349,399].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [12]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“With few exceptions, systematic targeting of Kv7, HCN, or GIRK channels in depression has lagged behind synaptic plasticity-based approaches, representing a major and underdeveloped opportunity for antidepressant discovery [12,27,30,31].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286 · cited 3×
“Longitudinal and mechanistic trials are urgently needed to clarify causality and optimize intervention strategies in psychiatric and neurodegenerative disorders [181,188,191].”
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Kwon, H. S., & Koh, S.-H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00221-2 · Cited by 2,595
Response of Phenylpropanoid Pathway and the Role of Polyphenols in Plants under Abiotic Stress
Sharma, A., Shahzad, B., Rehman, A., Bhardwaj, R., Landi, M., & Zheng, B. (2019) · Molecules · doi:10.3390/molecules24132452 · Cited by 2,038
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906 · cited 1×
“Albiflorin, a bioactive monoterpene glycoside, demonstrates a complementary mode of action: gut microbes metabolize it into benzoic acid, which penetrates the blood–brain barrier and inhibits D-amino acid oxidase, ultimately fostering neurogenesis and reducing depressive symptoms [275,276].”
Sheller, M. J., Edwards, B., Reina, G. A., Martin, J., Pati, S., Kotrotsou, A., Milchenko, M., Xu, W., Marcus, D., Colen, R. R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69250-1 · Cited by 1,646 · cited 1×
“Beyond efficacy, safety monitoring on a global scale provides crucial insight into rare adverse events and long-term tolerability [359,360,363].”
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586 · cited 1×
“Clinical translation represents the critical step of transforming mechanistic insights and preclinical discoveries into therapeutic strategies that can be safely and effectively applied in patient care [150,347,348].”
Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism
Gao, J., Xu, K., Liu, H., Liu, G., Bai, M., Peng, C., Li, T., & Yin, Y. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00013 · Cited by 1,298
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244 · cited 3×
“These multitarget, biocompatible candidates warrant rapid, translational exploration to transform MDD management [3,8].”
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Jacka, F. N., O’Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., Castle, D., Dash, S., Mihalopoulos, C., Chatterton, M. L., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0791-y · Cited by 1,093
Research works printed but not linked: 2
- Ribas, 2021, The different roles of Griffonia simplicifolia in the treatment of depression: A narrative review, Int. J. Complement. Alt. Med., 14, 167
- Moosavi, 2016, Modulation of neurotrophic signaling pathways by polyphenols, Drug Des. Devel Ther., 10, 23
Cited by
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Self-citationJuhász, L., Galla, Z., Tanaka, M., & Vécsei, L. (2026) · Antioxidants · doi:10.3390/antiox15020261 · Cited by 10
Self-citationRammal, H., Noonan, A. M., Rivas, D., Sibai, D. S., Marcangeli, V., & Duque, G. (2026) · Biochimie · doi:10.1016/j.biochi.2026.02.016 · Cited by 2
Wang, X., Piao, Y., Xia, B., Chu, W., Yao, X., & Li, W. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1834069 · Cited by 1
Tanaka, M., & Vécsei, L. (2026) · EXCLI journal · doi:10.17179/excli2026-9522 · Cited by 3
Self-citation
Metadata
- Authors
- Chehadi, A. C., Pereira de Lima, E., Detregiachi, C. R. P., Santos de Argollo Haber, R., Catharin, V. M. C. S., Fornari Laurindo, L., Engracia Valenti, V., Machado Galhardi, C., Tanaka, M., & Maria Barbalho, S.
- Affiliations
- Universidade de Marília (BR)
- Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil
- Graduate Program in Structural and Functional Interactions in Rehabilitation, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil
- Division of Cellular Growth, Hemodynamic and Homeostasis Disorders, Graduate Program in Medical Sciences, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo 01246-903, SP, Brazil
- Department of Cardiovascular and Metabolic Health, School of Philosophy and Sciences, Universidade Estadual Paulista (UNESP), Marília 17525-900, SP, Brazil
- University of Szeged (HU)
- Corresponding author
- Tanaka, Masaru
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-01-01
- Volume
- 27
- Issue
- 1
- Pages
- 465
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC12787022
- OpenAlex
- W7118002548
- Cited by
- 8
- References
- 431
- Citations by year
- 2026: 8
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- HUN-REN Hungarian Research Network
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- tryptophan metabolism, major depressive disorder, 5-hydroxytryptophan, isoflavones, berberine, polyphenols, phytochemicals, kynurenine pathway, gut-brain-immune axis, inflammation, neuroplasticity, anxiety, sleep regulation, cognitive function, precision psychiatry, dietary intervention
- MeSH terms
- Animals, Antidepressive Agents, Depression, Major Depressive Disorder, Depressive Disorder, Major, Diet, Humans, Neurobiology, Tryptophan
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Harnessing Dietary Tryptophan: Bridging the Gap Between Neurobiology and Psychiatry in Depression Management. https://app.cochat.ai/papers/10.3390/ijms27010465
- The paper
- Chehadi, A. C., Pereira de Lima, E., Detregiachi, C. R. P., Santos de Argollo Haber, R., Catharin, V. M. C. S., Fornari Laurindo, L., Engracia Valenti, V., Machado Galhardi, C., Tanaka, M., & Maria Barbalho, S. (2026). Harnessing Dietary Tryptophan: Bridging the Gap Between Neurobiology and Psychiatry in Depression Management. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010465
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.